Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
3,251
datasets available to search
ShareScore release 0.9.0
Dataset results
3,251 results for “ovarian cancer”
MiRoR2 - P1 - Shortcomings in the evaluation of biomarkers in ovarian cancer: a systematic review
<p>Data set for the study “Shortcomings in the evaluation of biomarkers in ovarian cancer: a systematic review”, including search strategy, extraction form, extracted data with summary of results, and protocol</p>
Patient-derived and artificial ascites have minor effects on MeT-5A mesothelial cells and do not facilitate ovarian cancer cell adhesion
<p>Raw data of "Patient-derived and artificial ascites have minor effects on MeT-5A mesothelial cells and do not facilitate ovarian cancer cell adhesion".</p>
Immunogenomic analyses of high-grade serous ovarian cancer (HGSOC)
<p>High-grade serous ovarian cancer (HGSOC) remains the most lethal gynecologic malignancy despite new therapeutic concepts, including poly-ADP-ribose polymerase inhibitors (PARPis) and antiangiogenic therapy. In this study, we have analyzed homologous recombination repair deficiency (HRD) or BRCAness and the composition of the tumor microenvironment, which appear to play a critical role in determining the therapeutic response of combination immunotherapy with PARPis. The used datasets include RNA sequencing data and clinical information from patients of a new HGSOC cohort of the Medical University of Innsbruck (MUI) (n=60) and analyzed data from The Cancer Genome Atlas (TCGA) (n=226).</p>
Small extracellular vesicles from malignant ascites of patients with advanced ovarian cancer provide insights into the dynamics of the extracellular matrix
<p>Representative Atomic Force Microscope images collected in liquid on Extracellular Vesicles from Ascite and Cell cultures. Data were collected by Broker Multimode VIII. Images like these were used in the paper to measure the contact angle and size distribution.</p>
Raw data used in the manuscript titled "Metabolomic Analysis of Histological Composition Variability of High-Grade Serous Ovarian Cancer Using 1H HR MAS NMR Spectroscopy "
<p>The folder contains raw data used in the manuscript titled "Metabolomic Analysis of Histological Composition Variability of High-Grade Serous Ovarian Cancer Using <sup>1</sup>H HR MAS NMR Spectroscopy ".</p> <p> </p> <p> Raw data measured on Bruker Avance III 400 MHz NMR spectrometer:</p> <p>- 1D <sup>1</sup>H HR MAS NMR spectra (path: <em>Patient_code – Sample_code/500/fid</em>)</p> <p>- 2D <sup>1</sup>H-<sup>1</sup>H J-resolved HR MAS NMR spectra (path: <em>Patient_code – Sample_code/600/ser</em>).</p> <p> </p> <p>Metadata is included in <em>Metadata.xlsx</em> file.</p> <p>Each sample is described with the following parameters:</p> <p>- patient code (after anonymization),</p> <p>- sample code (the label <em>l</em> or <em>r</em> denotes the <em>left</em> or <em>right</em> ovary in patients from whom samples were obtained bilaterally),</p> <p>- sample weight,</p> <p>- clinic-pathological parameters (such as: age, BMI, menopausal status, diagnosis, FIGO stage),</p> <p>- percentage tissue content obtained from histopathological analysis after HR MAS NMR studies (cancer cells, epithelial compartment within benign tumors, necrosis, inflammation, fibrosis, calcification, normal ovary, vessels, fatty tissue).</p> <p> </p> <p>Some samples were considered representative of particular tissue components:</p> <p>- cancer (HGSOC) compartment,</p> <p>- fibrotic stroma within malignant (HGSOC) tumors,</p> <p>- fibrotic stroma within benign tumors,</p> <p>- normal ovary tissue (the samples collected from the control group),</p> <p>- normal ovary tissue (the samples collected from the cancer patients),</p> <p>- necrosis,</p> <p>- non-tumoral fibrous tissue / fibrous tumor capsule (obtained from the patients with benign non-neoplastic lesions)</p> <p>- corpus albicans</p> <p>The assignment of the samples to these categories is indicated in the column <em>Tissue components.</em></p> <p><em> </em></p> <p>The samples classified as outliers in PCA model 1 are indicated in the column <em>Outliers</em>.</p> <p>The samples included in multivariate models are indicted in the columns: <em>PCA 2, PCA 3, PCA 4, PCA 5, PCA 5a, PCA 6, OPLS-DA 1, OPLS-DA 2, OPLS-DA 3, OPLS-DA 4, OPLS-DA 5, OPLS-DA 6 and OPLSR.</em></p> <p><em> </em></p>
Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
ClinicalTrials.gov study NCT00866697. IPD Sharing: UNDECIDED. Countries: 17. Publications: 7.
Japan Phase 2 Study of Niraparib (Maintenance Therapy) in Participants With Relapsed Ovarian Cancer
ClinicalTrials.gov study NCT03759587. IPD Sharing: YES. Countries: 1. Publications: 2.
Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected
ClinicalTrials.gov study NCT04729387. IPD Sharing: YES. Countries: 26. Publications: 1.
REVITALIZE: A Telehealth Intervention for Women With Advanced Ovarian Cancer and PARP Inhibitor-Related Fatigue
ClinicalTrials.gov study NCT04525183. IPD Sharing: YES. Countries: 1. Publications: 1.
Japan Phase 2 Study of Niraparib in Participants With Advanced, Relapsed Ovarian Cancer
ClinicalTrials.gov study NCT03759600. IPD Sharing: YES. Countries: 1. Publications: 2.
Data from: Screening familial risk for hereditary breast and ovarian cancer
Open the record for dataset details and reuse information.
Mutational Profiling in Epithelial Ovarian Cancer: A Meta-Analysis of 435 Patients Dataset
<p><strong>Data Description</strong></p> <p>0 represents no mutation, 1 represents a mutation</p> <p>Survive relates to the survival outcome of the patient. SurviveTime is in days (7300 chosen for alive patients).</p> <p>Ovarian Cancer Patients</p> <ul> <li>361 count</li> <li>TP53, BRCA1, BRCA2, KMT2C, CDK12, CSMD3, TTN, MUC16, NF1, PALB2, RB1, PTEN, FOXM1, BRIP1, KRAS, RASA1, CHEK2, RAD50, RAD51C/D, MRE11A, NBN, FANCE, FANCD2, ATR, ATM, MSH2, PMS2, MLH1, MSH6, FAT1, FAT2, FAT3, FAT4</li> </ul> <p>Uterine Cancer Patients</p> <ul> <li>437 count</li> <li>MSH6, CDK12, PMS2, BRIP1, FAT1, CSMD3, FAT4, BRCA2, MUC16, PALB2, KRAS, BRCA1, MSH2, PTEN, TP53, NF1, KMT2C, FAT3, FANCD2, ATM, NBN, ATR, CHEK2, FANCE, MLH1</li> </ul> <p>Cervical Cancer Patients</p> <ul> <li>174 count</li> <li>CSMD3, CDK12, FAT1, BRIP1, RB1, FAT4, BRCA2, MUC16, PALB2, KRAS, TP53, PTEN, KMT2C, FAT3, BRCA1, NF1, ATM, FANCD2, NBN, ATR, MLH1</li> </ul>
A 3D multi-cellular tissue model of the human omentum to study mechanisms of ovarian cancer metastasis
<p>Here, the design of 3D multi-cellular tissue model of the human omentum is presented to study mechanisms of ovarian cancer metastasis.</p>
Proteome association studies of breast, prostate, ovarian, and endometrial cancers implicate plasma protein regulation in cancer susceptibility
<p>Full results datasets for Proteome association studies of breast, prostate, ovarian, and endometrial cancers implicate plasma protein regulation in cancer susceptibility:</p> <p>ALL*all_pheno.csv are TOPMed-MESA combined-ancestry models, discovery and replication cohorts</p> <p>ARIC_EA_all_pheno.csv is ARIC European-American ancestry models, discovery cohort</p> <p>ARIC*meta_all.txt is ARIC European-American ancestry models, discovery and replication cohorts, with meta-analysis of disc+rep</p>
BLM overexpression as a predictive biomarker for CHK1 inhibitor response in PARP inhibitor–resistant BRCA-mutant ovarian cancer
<p>PARP inhibitors (PARPis) have changed the treatment paradigm in BRCA-mutant high-grade serous ovarian carcinoma (HGSC). However, most patients eventually develop resistance to PARPis, highlighting an unmet need for novel therapeutic strategies. Using high-throughput drug screens, we identified ATR/CHK1 pathway inhibitors as cytotoxic, and further validated monotherapy activity of the CHK1 inhibitor (CHK1i), prexasertib, in PARPi-resistant BRCA-mutant HGSC cells and animal models. As a proof-of-concept trial, we conducted a phase II study of prexasertib in BRCA-mutant HGSC patients. The treatment was well-tolerated but yielded an objective response rate of 6% (1/17; 1 PR) in patients with prior PARPi treatment. Exploratory biomarker analyses revealed that replication stress and fork stabilization were associated with clinical benefit to CHK1i. In particular, overexpression of BLM, and CCNE1 overexpression or copy number gain/amplification were seen in patients deriving durable benefit from CHK1i. Our findings suggest replication fork–related biomarkers should be further evaluated for CHK1i sensitivity in HGSC.</p>
Ojeok-san Enhances Platinum Sensitivity in Ovarian Cancer by Regulating Adipocyte Paracrine IGF1 Secretion
<p><strong>Figure 1 Adipocytes promote platinum drug resistance in OvCa cells</strong></p> <p>(A-B) The effects of Adipo-CM treatment on cell viability and apoptosis level were detected by CCK-8 and flow cytometry. (C) The expression of proliferation-related and apoptosis-related proteins was detected by western blot. (D) The IC<sub>50</sub> values of different concentrations of cisplatin and carboplatin treatment on OvCa cells were detected by CCK-8. * <em>p</em><0.05.</p> <p> </p> <p><strong>Figure 2 Adipocytes promote OvCa resistance to platinum drugs through paracrine secretion of IGF1</strong></p> <p>(A) The expression of IGF1 in HPAd cells was detected by western blot. (B) The concentration of IGF1 in culture media of HPAd cells was detected by ELISA. (C-D) The effects of different treatments on SKOV3 cell viability and apoptosis level were detected by CCK-8 and flow cytometry. (E) The expression of proliferation-related and apoptosis-related proteins was detected by western blot. (F) The IC<sub>50</sub> values of different concentrations of cisplatin and carboplatin treatment on SKOV3 cells were detected by CCK-8. *VS oe-NC+DMSO, #VS oe-IGF1+DMSO, * <em>p</em><0.05.</p> <p> </p> <p><strong>Figure 3 OJS inhibits adipocyte paracrine secretion of IGF1 to regulate OvCa progression</strong></p> <p>(A-B) The expression of IGF1 in HPAd cells and cell culture supernatant was detected by western blot and ELISA, respectively. (C-D) The effects of different treatments on SKOV3 cell viability and apoptosis level were detected by CCK-8 and flow cytometry. (E) The expression of proliferation-related and apoptosis-related proteins was detected by western blot. (F) The IC<sub>50</sub> values of different concentrations of cisplatin and carboplatin treatment on SKOV3 cells were detected by CCK-8. *VS Adipo-CM, #VS Adipo-CM2, <em>p</em><0.05.</p> <p> </p> <p><strong>Figure 4 OJS enhances the anticancer activity of cisplatin in SKOV3 and HPAd xenograft models</strong></p> <p>(A-C) Tumor growth under different treatments. (D) The effects of OJS and cisplatin on the damage and morphological changes of major organs in mice were detected by H&E staining. (E) The expression of proliferation-related and apoptosis-related proteins was detected by IHC. *VS control, #VS cisplatin, <em>p</em><0.05.</p> <p> </p>
ZD4054 (Zibotentan) or Placebo Plus Chemotherapy in Patients With Advanced Ovarian Cancer
ClinicalTrials.gov study NCT00929162. IPD Sharing: Not stated. Countries: 2. Publications: 1.
Vorinostat, Carboplatin and Gemcitabine in Women With Recurrent, Platinum-Sensitive Ovarian Cancer
ClinicalTrials.gov study NCT00910000. IPD Sharing: NO. Countries: 1. Publications: 1.
Best Approach in Recurrent-Ovarian-Cancer-with Cediranib-Olaparib
ClinicalTrials.gov study NCT03314740. IPD Sharing: Not stated. Countries: 1. Publications: 2.
AZD0530 Phase II Study in Patients With Advanced Ovarian Cancer
ClinicalTrials.gov study NCT00610714. IPD Sharing: Not stated. Countries: 12. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.